Cost Utility Analysis (CUA) of Nivolumab Compared To Everolimus for The Treatment of Metastatic Renal Cell Carcinoma (RCC) in Australia
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.260
https://www.valueinhealthjournal.com/article/S1098-3015(17)30594-6/fulltext
Title :
Cost Utility Analysis (CUA) of Nivolumab Compared To Everolimus for The Treatment of Metastatic Renal Cell Carcinoma (RCC) in Australia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30594-6&doi=10.1016/j.jval.2017.08.260
First page :
A444
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
243